• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 29, 2020

View Archived Issues
Lung cancer illustration

Just Adaurable: Astrazeneca’s phase III Tagrisso data captivate at ASCO

Astrazeneca plc’s Tagrisso (osimertinib) seems poised to become standard of care in the adjuvant setting for early stage (IB, II and IIIA) EGFR-mutated non-small-cell lung cancer (NSCLC), thanks to phase III data from the study called Adaura, made public at the American Society of Clinical Oncology (ASCO) meeting. Read More

Preclinical ASCO data lift RNAi firm Phio’s shares

Positive preclinical data from Phio Pharmaceuticals Inc., of Marlborough, Mass., propelled the company stock (NASDAQ:PHIO) dramatically upward, about 86%, at midday Friday only to see it finally settle at a more modest 36.16% increase to close May 29 at $3.05. Read More
Psychology-disorders-heads

Pivotal schizophrenia trial bust sends Minerva shares tumbling

A phase III test of roluperidone, a drug developed by Minerva Neurosciences Inc. with a goal of treating negative symptoms in schizophrenia, found that the experimental medicine failed to deliver statistically significant differences vs. placebo in improving both the trial's primary endpoint, a common measure of symptom severity, and its secondary endpoint, a score measuring social function. Read More

Imminent Ebola vaccine approval in Europe a historic first for J&J’s Advac platform

DUBLIN – Johnson & Johnson’s Janssen Biotech arm is on the brink of a historic first vaccine approval, having secured a positive vote May 29 from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for its prime-boost Ebola virus vaccine combo, Zabdeno (Ad26.Zebov) plus MVABEA (MVA-BN-Filo). Read More
Jenner-vaccine-pic-4-17

WHO launches COVID-19 patent pool, backed by 35+ countries

LONDON – The World Health Organization (WHO) is stepping up its effort to try and ensure equitable access to any approved COVID-19 vaccines and therapies, putting in place a system for sharing all intellectual property, information and clinical trials data needed to enable generic manufacturing. Read More

Chinese cell therapy developers adopt new approaches to stand out

SUZHOU, China – Chinese CAR T therapy developers from early to IPO-ready-stage are confident that they can create a strong presence in the global scene with their innovations, and they are also making strategies that will work best for their home market. Read More

Qurient to start phase I trials for triple kinase inhibitor Q-702

HONG KONG – South Korea’s Qurient Co. Ltd., located in Gyeonggi-do, is preparing to send its novel drug, Q-702, into the clinic after receiving clearance from the U.S. FDA, roughly a month after submitting the application on April 24. Read More
Courts1.png

Presumption in favor of petitioner seen as most critical piece of PTO response to SAS v. Iancu

The U.S. Patent and Trademark Office (PTO) has posted a notice of proposed rulemaking in response to a case decided by the Supreme Court in 2018, SAS v. Iancu, and the first item on the PTO agenda is to formally require that an inter partes review (IPR) consist of an exhaustive review of all the claims contested by the petitioner. Read More
Cardiovascular.png

Bench Press for May 29, 2020

BioWorld looks at translational medicine, including: iPSC microtissue gives clues to heart disease; Tumor types have distinct microbiomes; Kinase helps prepare pre-metastatic niche; EZH2 has dual role; New alcohol risk genes in Caucasians; Assay system identifies mitochondria-targeting drugs for PD; Imitating ticks to evade immunity; Ovarian organoids implicate oviducts. Read More

Appointments and advancements for May 29, 2020

New hires and promotions in the biopharma industry, including: Hansa, Ipsen, Sanofi. Read More

Conference data for May 29, 2020: ASCO

New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology’s annual meeting May 29-31, including: Adaptimmune, Affimed, Agios, Alligator, Allogene, Alteogen, Alx, Amgen, Amphivena, Arvinas, Astrazeneca, Athenex, Autolus, Aveo, Bayer, Beigene, Bio-Path, Boundless, Briacell, Bridgebio, Cardiff Oncology, Celltrion, Cytomx, Daiichi, Deciphera, Effector, Eisai, Foundation Medicine, Genocea, Gilead, Gossamer, Harpoon, Heat Biologics, Immunogen, Iovance, IMV, Karyopharm, Kiadis, Kura, Marker, Merck KGaA, Merck, Nextcure, Novartis, Oncolytics, Pfizer, Regeneron, Rgenix, Sanofi, Seattle Genetics, Servier Silverback, Takeda, TG, Tolero, Trillium, Ziopharm. Read More

Financings for May 29, 2020

Biopharmas raising money in public or private financings, including: Arcus, Genetic Technologies, Iovance, Legend Biotech, Marinus, Mersana, Palvella. Read More

In the clinic for May 29, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achilles, Adverum, Aveo, Bio-Path, BMS, Chiesi, Corvus, Eloxx, Galera, Janssen, Minerva, Molecular Partners, Myovant. Read More

Other news to note for May 29, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acelrx, Agex, Arrevus, Biogen, Boston Biomedical, Chondrial, Daiichi Sankyo, Icagen, Immutep, Larimar, Melinta, Merck, Orpro, QED, Roche, Sernova, Sumitomo Dainippon Pharma Oncology, Shire, Takeda, Tetraphase, Tolero, Turning Point, Vir, Zafgen. Read More

Regulatory actions for May 29, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astellas, Boehringer, Chi-Med, Immune-Onc, J&J, Lilly, Menlo, Nabriva, Novartis, Onxeo, Orphazyme, Roche, Santhera, Takeda. Read More
coronavirus-COVID-19-globe.png

More than half of biopharma/nonprofit deals in April and May focused on COVID-19

Few would dispute that the best way to find innovative solutions to the COVID-19 pandemic is through industry, academia and government working together. BioWorld data indicate that more than 45% of the biopharma deals with nonprofit entities (bio/nonprofit) in 2020 are indeed focused on fighting the globally-disruptive SARS-CoV-2 virus. Read More

Biopharma money raised: Jan. 1-May 28, 2020

Year-to-date money raised in public, private and other financings of biopharma companies. Read More

Money raised by biopharma: 2020 vs. 2019

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019. Read More

Biggest gainers and losers for the week of May 25-29, 2020

The top 10 biopharma stock gainers and losers for the week. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • Philochem, BMS ink $1.35B deal for prostate cancer candidate OncoACp3

    BioWorld
    Philochem AG’s ligand-targeting approach drew to the table Bristol Myers Squibb Co. in a potential $1.35 billion agreement granting BMS subsidiary Rayzebio Inc....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe